MedTrace Logo

[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers

NCT02108457 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2021-03-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effect of specific bone marrow maps developed with18F-FLT PET/CT imaging on the ability to spare proliferating bone marrow using proton beam radiotherapy compared to IMRT. Participants will be 18 years of age or old with a history of gynecologic cancer. Subjects will undergo 3 FLT-PET scans (one before treatment, one during the course of RT, and one 2-5 weeks after initiation of RT). Scans will take place in the Department of Radiation Oncology.

Conditions

  • Gynecologic Cancer

Interventions

RADIATION

[18F]Fluorothymidine (FLT) PET/CT Imaging

Sponsors & Collaborators

  • Abramson Cancer Center at Penn Medicine

    lead OTHER

Principal Investigators

  • Lilie Lin, MD · Abramson Cancer Center at Penn Medicine

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2016-12-21
Completion
2016-12-21

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02108457 on ClinicalTrials.gov